A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Public ClinicalTrials.gov record NCT03052725. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multicenter, open-label (OL) extension study to obtain additional long-term safety data for subcutaneous (sc) administration of reslizumab treatment administered at a fixed dose of 110 mg in patients 12 years of age and older with severe eosinophilic asthma who completed the treatment period of a placebo-controlled Phase 3 trial of sc reslizumab. The study consists of a screening/baseline visit followed by a 36-week OL treatment period and a 15-week follow-up period.
Study identification
- NCT ID
- NCT03052725
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 391 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 10, 2017 (Actual)
- Primary completion
- Feb 22, 2018 (Actual)
- Completion
- Feb 22, 2018 (Actual)
- Last update posted
- Dec 14, 2022
2017 – 2018
United States locations
- U.S. sites
- 37
- U.S. states
- 20
- U.S. cities
- 34
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Teva Investigational Site 14647 | Birmingham | Alabama | 35209 | — |
| Teva Investigational Site 14631 | Bakersfield | California | 93301 | — |
| Teva Investigational Site 14648 | Huntington Beach | California | 92647 | — |
| Teva Investigational Site 14637 | Napa | California | 94558 | — |
| Teva Investigational Site 14654 | Stockton | California | 95207 | — |
| Teva Investigational Site 14636 | Walnut Creek | California | 94598 | — |
| Teva Investigational Site 14626 | Aventura | Florida | 33180 | — |
| Teva Investigational Site 14634 | Homestead | Florida | 33030 | — |
| Teva Investigational Site 14650 | Miami | Florida | 33015 | — |
| Teva Investigational Site 14629 | Miami | Florida | 33173 | — |
| Teva Investigational Site 14619 | Miami | Florida | 33186 | — |
| Teva Investigational Site 14624 | Orlando | Florida | 32819 | — |
| Teva Investigational Site 14638 | Tallahassee | Florida | 32308 | — |
| Teva Investigational Site 14642 | Buford | Georgia | 30518 | — |
| Teva Investigational Site 14651 | Chicago | Illinois | 60612 | — |
| Teva Investigational Site 14645 | Michigan City | Indiana | 46360 | — |
| Teva Investigational Site 14620 | Owensboro | Kentucky | 42301 | — |
| Teva Investigational Site 14623 | Lafayette | Louisiana | 70508 | — |
| Teva Investigational Site 14627 | North Dartmouth | Massachusetts | 02747 | — |
| Teva Investigational Site 14644 | Boys Town | Nebraska | 68010 | — |
| Teva Investigational Site 14652 | Ocean City | New Jersey | 07712 | — |
| Teva Investigational Site 14632 | Lake Success | New York | 11042 | — |
| Teva Investigational Site 14646 | New York | New York | 10016-9196 | — |
| Teva Investigational Site 14633 | Cincinnati | Ohio | 45221 | — |
| Teva Investigational Site 14653 | Cleveland | Ohio | 44106 | — |
| Teva Investigational Site 14621 | Edmond | Oklahoma | 73034 | — |
| Teva Investigational Site 14625 | Edmond | Oklahoma | 73034 | — |
| Teva Investigational Site 14643 | Jenkintown | Pennsylvania | 19046 | — |
| Teva Investigational Site 14622 | Pittsburgh | Pennsylvania | 15241 | — |
| Teva Investigational Site 14630 | East Providence | Rhode Island | 02914 | — |
| Teva Investigational Site 14649 | Providence | Rhode Island | 02909 | — |
| Teva Investigational Site 14655 | Knoxville | Tennessee | 37919 | — |
| Teva Investigational Site 14639 | Corsicana | Texas | 75110 | — |
| Teva Investigational Site 14640 | Dallas | Texas | 75225 | — |
| Teva Investigational Site 14641 | Provo | Utah | 84604 | — |
| Teva Investigational Site 14628 | Abingdon | Virginia | 24210 | — |
| Teva Investigational Site 14635 | Falls Church | Virginia | 22044 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 97 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03052725, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 14, 2022 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03052725 live on ClinicalTrials.gov.